Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (41-50 of 158) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group studyGrazia Arpino, Stephanie J Green, D Craig Allred, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancerTorsten A Hopp, Heidi L Weiss, Irma S Parra, et al.
Cancer Research|August 17, 2006
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancerSuleiman Massarweh, C Kent Osborne, Shou Jiang, et al.
Journal of the National Cancer Institute|May 2, 2007
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapyGrazia Arpino, Carolina Gutierrez, Heidi Weiss, et al.
Cancer|January 19, 2010
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi, Priya B Shetty, Heidi L Weiss, et al.
Advances in Experimental Medicine and Biology|January 17, 2025
HER2-Positive Breast Cancer Treatment and ResistanceJamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)Nancy E Davidson, Anne M O'Neill, Allen M Vukov, et al.
Journal of Behavioral Medicine|May 15, 2007
Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast cancerLois C Friedman, Catherine Romero, Richard Elledge, et al.
Cancer Research|February 5, 2008
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionSuleiman Massarweh, C Kent Osborne, Chad J Creighton, et al.
Breast Cancer Research and Treatment|March 17, 2006
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growthJana Divisova, Isere Kuiatse, ZaWaunyka Lazard, et al.
Pageof 16

Showing results (41-50 of 158) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group studyGrazia Arpino, Stephanie J Green, D Craig Allred, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancerTorsten A Hopp, Heidi L Weiss, Irma S Parra, et al.
Cancer Research|August 17, 2006
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancerSuleiman Massarweh, C Kent Osborne, Shou Jiang, et al.
Journal of the National Cancer Institute|May 2, 2007
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapyGrazia Arpino, Carolina Gutierrez, Heidi Weiss, et al.
Cancer|January 19, 2010
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi, Priya B Shetty, Heidi L Weiss, et al.
Advances in Experimental Medicine and Biology|January 17, 2025
HER2-Positive Breast Cancer Treatment and ResistanceJamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)Nancy E Davidson, Anne M O'Neill, Allen M Vukov, et al.
Journal of Behavioral Medicine|May 15, 2007
Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast cancerLois C Friedman, Catherine Romero, Richard Elledge, et al.
Cancer Research|February 5, 2008
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionSuleiman Massarweh, C Kent Osborne, Chad J Creighton, et al.
Breast Cancer Research and Treatment|March 17, 2006
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growthJana Divisova, Isere Kuiatse, ZaWaunyka Lazard, et al.
Pageof 16